Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results

被引：0
|
作者：
Voskoboynik, M. [1 ]
Mileshkin, L. [2 ]
Gan, H. [3 ]
Millward, M. [4 ]
Au-Yeung, G. [2 ]
Meniawy, T. M. [4 ]
Kichenadasse, G. [5 ]
Zhang, K. [6 ]
Zhang, M. [7 ]
Mu, S. [8 ]
Lickliter, J. D. [1 ]
机构：
[1] Nucleus Network, Oncol, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[3] Austin Hosp, Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia
[4] Linear Clin Res, Oncol, Nedlands, WA, Australia
[5] Flinders Med Ctr, Flinders Ctr Innovat Canc, Bedford Pk, SA, Australia
[6] BeiGene USA Inc, Biostat, Emeryville, CA USA
[7] BeiGene USA Inc, Clin Sci, Emeryville, CA USA
[8] BeiGene USA Inc, Clin Pharmacol, Emeryville, CA USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
452PD
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors.
    Lickliter, Jason D.
    Gan, Hui Kong
    Meniawy, Tarek
    Yang, Jason
    Wang, Lai
    Luo, Lusong
    Lu, Ni
    Millward, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Preliminary results of pamiparib (BGB-290), a PARP1/2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors
    Johnson, M.
    Galsky, M.
    Barve, M.
    Goel, S.
    Park, H.
    Du, B.
    Mu, S.
    Ramakrishnan, V.
    Wood, K.
    Wang, V.
    Lakhani, N.
    ANNALS OF ONCOLOGY, 2018, 29 : 138 - 138
  • [3] Dose escalation/expansion study to investigate the safety, pharmacokinetics, food effect, and antitumor activity of BGB-290 in patients with advanced solid tumors
    Lickliter, J.
    Mileshkin, L.
    Voskoboynik, M.
    Millward, M.
    Freimund, A.
    Meniawy, T.
    Tang, T.
    Wei, R.
    Li, M.
    Paton, V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
    Lickliter, Jason D.
    Voskoboynik, Mark
    Mileshkin, Linda
    Gan, Hui K.
    Kichenadasse, Ganessan
    Zhang, Kathy
    Zhang, Maggie
    Tang, Zhiyu
    Millward, Michael
    BRITISH JOURNAL OF CANCER, 2022, 126 (04) : 576 - 585
  • [5] Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
    Jason D. Lickliter
    Mark Voskoboynik
    Linda Mileshkin
    Hui K. Gan
    Ganessan Kichenadasse
    Kathy Zhang
    Maggie Zhang
    Zhiyu Tang
    Michael Millward
    British Journal of Cancer, 2022, 126 : 576 - 585
  • [6] Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
    Jason D. Lickliter
    Mark Voskoboynik
    Linda Mileshkin
    Hui K. Gan
    Ganessan Kichenadasse
    Kathy Zhang
    Maggie Zhang
    Zhiyu Tang
    Michael Millward
    British Journal of Cancer, 2022, 126 : 310 - 310
  • [7] Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (Id) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours
    Stradella, A.
    Johnson, M. L.
    Goel, S.
    Chandana, S. R.
    Galsky, M. D.
    Calvo, E.
    Moreno, V.
    Park, H.
    Arkenau, H. -T.
    Cervantes, A.
    Farinas Madrid, L.
    Mileshkin, L.
    Plummer, R.
    Evans, J.
    Horvath, L.
    Prawira, A.
    Pelham, R. J.
    Mu, S.
    Andreu-Vieyra, C.
    Barve, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 166 - +
  • [8] Phase I dose-escalation and expansion study of the PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumours
    Li, H.
    Xu, J.
    Shao, B.
    Liu, R.
    Ran, R.
    Song, G.
    Jiang, H.
    Wang, K.
    Shi, Y.
    Liu, J.
    Hu, W.
    Chen, F.
    Zhang, G.
    Wang, Y.
    Zhao, C.
    Ru, J.
    Wang, Q.
    Rugo, H. S.
    Li, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study
    Yonemori, Kan
    Shimizu, Toshio
    Kondo, Shunsuke
    Iwasa, Satoru
    Koyama, Takafumi
    Kitano, Shigehisa
    Sato, Jun
    Shimomura, Akihiko
    Shibaki, Ryota
    Suri, Ajit
    Kase, Yoichi
    Sumino, Shuuji
    Tamura, Kenji
    Yamamoto, Noboru
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (05) : 693 - 699
  • [10] BGB-290: A highly potent and specific PARP1/2 inhibitor potentiates antitumor activity of chemotherapeutics in patient biopsy derived SCLC models
    Tang, Zhiyu
    Liu, Ye
    Zhen, Qin
    Ren, Bo
    Wang, Hexiang
    Shi, Zhenyan
    Gong, Wenfeng
    Liu, Yong
    Wang, Xing
    Gao, Yajuan
    Yu, Fenglong
    Wu, Yiyuan
    Jiang, Bing
    Sun, Xuebing
    Wei, Min
    Zhou, Changyou
    Luo, Lusong
    Li, Zhengxiang
    Yu, Jiangyong
    Zhao, Jun
    Wang, Jie
    Wang, Lai
    CANCER RESEARCH, 2015, 75
12345